Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeoCura IM
- Development stage
- Preclinical
- Lead developer
- NeoCura
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
NeoCura IM is an mRNA-based tumor microenvironment immunomodulator being developed by NeoCura for the treatment of solid tumors. The therapeutic candidate consists of mRNA sequences encoding immunomodulatory cytokines or other specific immunoregulatory factors. Upon delivery, NeoCura IM utilizes the patient's own cells to express these cytokines, thereby modifying the immunosuppressive tumor microenvironment, activating both innate and adaptive immune responses, and enhancing antitumor immunity. It is designed to be used either as a monotherapy or in combination with other immunotherapies, such as immune checkpoint inhibitors, tumor vaccines, or cell therapies, to achieve synergistic antitumor efficacy.
Beyond the preview
Go deeper on NeoCura IM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoCura IM.